These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12623560)

  • 1. Biodegradable stents as a platform to drug loading.
    Tsuji T; Tamai H; Igaki K; Kyo E; Kosuga K; Hata T; Nakamura T; Fujita S; Takeda S; Motohara S; Uehata H
    Int J Cardiovasc Intervent; 2003; 5(1):13-6. PubMed ID: 12623560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-eluting biodegradable poly-D/L-lactic acid vascular stents: an experimental pilot study.
    Uurto I; Mikkonen J; Parkkinen J; Keski-Nisula L; Nevalainen T; Kellomäki M; Törmälä P; Salenius JP
    J Endovasc Ther; 2005 Jun; 12(3):371-9. PubMed ID: 15943514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular response and mechanical integrity of the new biodegradable polymer coated sirolimus-eluting PROLIM stent implanted in porcine coronary arteries.
    Milewski K; Gorycki B; Buszman PP; Jelonek M; Beaudry D; Lapointe JM; Guy LG; Abusamra M; Pająk J; Kinasz W; Wojakowski W; Leclerc G; Gil RJ; Buszman PE
    Kardiol Pol; 2012; 70(7):703-11. PubMed ID: 22825946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel biodegradable polymer-coated, paclitaxel-eluting stent inhibits neointimal formation in porcine coronary arteries.
    Buszman P; Milewski K; Zurakowski A; Pajak J; Liszka Ł; Buszman P; Musioł E; AbuSamra M; Trznadel S; Kałuza G
    Kardiol Pol; 2010 May; 68(5):503-9. PubMed ID: 20491008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting.
    Ward MR; Agrotis A; Kanellakis P; Hall J; Jennings G; Bobik A
    Arterioscler Thromb Vasc Biol; 2002 Jun; 22(6):940-8. PubMed ID: 12067902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent.
    Vogt F; Stein A; Rettemeier G; Krott N; Hoffmann R; vom Dahl J; Bosserhoff AK; Michaeli W; Hanrath P; Weber C; Blindt R
    Eur Heart J; 2004 Aug; 25(15):1330-40. PubMed ID: 15288161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoting endothelial recovery and reducing neointimal hyperplasia using sequential-like release of acetylsalicylic acid and paclitaxel-loaded biodegradable stents.
    Lee CH; Yu CY; Chang SH; Hung KC; Liu SJ; Wang CJ; Hsu MY; Hsieh IC; Chen WJ; Ko YS; Wen MS
    Int J Nanomedicine; 2014; 9():4117-33. PubMed ID: 25206303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model.
    Lincoff AM; Furst JG; Ellis SG; Tuch RJ; Topol EJ
    J Am Coll Cardiol; 1997 Mar; 29(4):808-16. PubMed ID: 9091528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and early clinical experience with a biodegradable polymer-based, rapamycin-eluting, Indian drug-eluting coronary stent: the BIO-RAPID study.
    Bhargava B; Karthikeyan G; Shankar PB; Seth S; Singh S; Pr U; Lal AV; Mohanty M
    Indian Heart J; 2008; 60(3):228-32. PubMed ID: 19240312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis.
    Kuchulakanti P; Waksman R
    Drugs; 2004; 64(21):2379-88. PubMed ID: 15481997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eptifibatide-eluting stent as an antiproliferative and antithrombotic agent: in vitro evaluation.
    Chitkara K; Hogrefe K; Vasa-Nicotera M; Swanson N; Gershlick AH
    J Invasive Cardiol; 2006 Sep; 18(9):417-22. PubMed ID: 16954580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological inhibition of coronary restenosis: systemic and local approaches.
    Guerra E; Byrne RA; Kastrati A
    Expert Opin Pharmacother; 2014 Oct; 15(15):2155-71. PubMed ID: 25145263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo Evaluation of Cenderitide-Eluting Stent (CES) II.
    Huang Y; Ng XW; Lim SG; Chen HH; Burnett JC; Boey YC; Venkatraman SS
    Ann Biomed Eng; 2016 Feb; 44(2):432-41. PubMed ID: 26178873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents.
    El-Hayek G; Bangalore S; Casso Dominguez A; Devireddy C; Jaber W; Kumar G; Mavromatis K; Tamis-Holland J; Samady H
    JACC Cardiovasc Interv; 2017 Mar; 10(5):462-473. PubMed ID: 28279314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxic vessel reaction to an absorbable polymer-based paclitaxel-eluting stent in pig coronary arteries.
    Jabara R; Chronos N; Tondato F; Conway D; Molema W; Park K; Mabin T; King S; Robinson K
    J Invasive Cardiol; 2006 Aug; 18(8):383-90. PubMed ID: 16877788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Nuclear Magnetic Resonance Spectroscopy as a Method for Evaluation of In Vivo Poly-l-Lactide Biodegradation Kinetics From Stent-Polymer Matrices: An Experimental Study Utilizing Porcine Model of In-Stent Restenosis.
    Orlik B; Buszman PP; Krauze A; Gąsior P; Desperak P; Pająk J; Kasperczyk J; Janas A; Jelonek M; Handzlik-Orlik G; Buszman PE; Milewski K
    J Cardiovasc Pharmacol Ther; 2016 Jan; 21(1):93-9. PubMed ID: 25944843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial Assessment of Strut Coverage of Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months After Stent Implantation by Optical Frequency Domain Imaging: The DISCOVERY 1TO3 Study (Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Biodegradable Polymer at 1, 2, and 3 Months).
    Chevalier B; Smits PC; Carrié D; Mehilli J; Van Boven AJ; Regar E; Sawaya FJ; Chamié D; Kraaijeveld AO; Hovasse T; Vlachojannis GJ
    Circ Cardiovasc Interv; 2017 Dec; 10(12):. PubMed ID: 29246909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation.
    Koppara T; Joner M; Bayer G; Steigerwald K; Diener T; Wittchow E
    Thromb Haemost; 2012 Jun; 107(6):1161-71. PubMed ID: 22535188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.